Author Archives: Patricia Inacio, PhD

Therapy for Alport Syndrome Advancing after Stock Sale, Reata Pharmaceuticals Announces

Reata Pharmaceuticals is expecting $115.9 million revenue from the public offering of some of its stock shares, which will support the clinical development of the company’s leading investigational therapy, bardoxolone methyl, for chronic kidney disease (CKD) caused by Alport syndrome. Bardoxolone is being tested in the Phase 2/3 trial, Cardinal (NCT03019185), currently recruiting…

Create your own user feedback survey